• European Landscape Assessment
  • HTA Decision Analysis
  • Payer Research and Advisory Boards
  • EU Joint Scientific Consultation
  • Key Country Market Insights
  • EU JCA PICO prediction


  • European HTA, price & reimbursement strategy
  • Lifecycle Management (LCM) Strategy
  • Value Story & Message Development
  • Evidence Gap Analysis
  • Evidence Generation Planning (incl. RWE & PLEG)
  • Value-based Price Potential
  • EU HTA/JCA Strategy
  • EU JCA process & governance design


  • EU JCA Dossier development
  • Country HTA Submissions
  • European Launch Management
  • Value Communications

Questions we answer

Is it worth launching your latest asset in Europe?
US and global biotechs come to AESARA Europe for expert, evidence-based, go/no-go market access advice
What should you invest in Europe – and when?
US and global biotechs hire AESARA Europe for asset due diligence, value-based pricing, and European market access infrastructure build
Will European payers value your medical innovation?
US and global biotechs use AESARA’s European market access industry veterans to optimise their value evidence and product value propositions for European HTA
How should you best structure and sequence your European HTA submissions for strategic impact and operational efficiency?
US and global biotechs use AESARA's European and in-country experts to plan and execute successful HTA and pricing and reimbursement submissions
What value evidence will European HTA bodies need to see in support of your value story, target population, & price?
Global biopharma companies trust AESARA's insight and experience to test and optimise value propositions and value evidence plans, for European HTA and reimbursement success
How should we best prepare for the new, centralised, European HTA?​
Biotech and pharma innovators use AESARA Europe’s unique blend of HTA strategy and management consulting professionals to build structures, processes, governance, and submissions for EU Joint Clinical Assessment​
Previous slide
Next slide

Strategy leaders

Gavin J. Outteridge, MA (Oxon) 

is the Managing Director of Europe for AESARA. Gavin delivers measurable business improvement for global life sciences clients through advising executives on value & access strategy, communications and organizational design.

With over 25 years of leadership experience, including 20 in life sciences, Gavin believes the life sciences sector is a social good and that a regulated market is the best way of delivering innovation and value. Consequently, he works with clients in Development and Commercialization functions to optimize how they demonstrate scientifically-sound cost-risk-benefit and, by doing so, deliver value to patients, to payers and to investors.

Prior to AESARA, Gavin was on the Executive Committee of life sciences services company Kinapse; held a change management role in Pfizer R&D; and began his working life as an officer in the Royal Air Force.

Cristina Masseria, PhD, MSc

is an expert in health economics, market access, pricing, RWE, and health policy in Italy, Europe, the US and globally. She brings direct, rich experience across the product lifecycle and therapeutic areas, including oncology in both the pharmaceutical industry (Pfizer, GSK) and academia (LSE).

Cristina has a track record of success in developing and executing impactful and innovative value and access strategies. She enjoys working in matrix organizations as she believes the best ideas and initiatives happen when people from diverse backgrounds and opinions find solutions together. She is motivated by positively impacting people’s livesand by building high functioning teams.

Cristina holds an MSc and PhD in Economics from the Università Politecnica delle Marche, and an MSc in Health Economics from the University of York.

Catherine Chamoux, PhD

has international experience acquired over thirty+ years in the pharma industry in medium-sized and large companies. She holds a PhD in Pharmacy and a Masters of Public Health from Sciences Po, Paris. She is an expert in Market Access for innovative drugs.

As a member of the leadership team of the French affiliate of a leading US biotech for 15 years, she helped establish & develop the company locally, directly negotiated product prices & access conditions, developed relationships with regulators, payors and KOLs. She also actively participated in the evidence generation and early access program strategies for our innovative therapies, including orphan drug products, highlighting the unmet needs and the products’ unique attributes.

She also has strong pan-European experience in Market Access, having most recently led the Market Access Excellence function for Europe, creating common understanding, tools, measures and co-operation between countries.

Sameera Tak, MSc

Based in the Zug, Switzerland, biotech hub, Sameera has taken on the Geschäftsführerin or operational board director role, running AESARA Europe’s newly established Swiss operations.

Sameera brings differentiated breadth of experience as well as depth of expertise to her consulting role as a peer thought partner to the industry clients.

Sameera’s market access experiences ranges from global to regional roles with expertise in payor value communication strategies, European Field Value and access communications, pricing and access strategies, portfolio and brand level competitor readiness, Tender and contracts management strategies and tactical execution.

With nearly 16 years in the biopharmaceutical industry across market access as well as R&D roles across Global and Regional levels in large and mid- sized biopharma companies gives her a well-rounded insight into strategic and tactical client needs.

Prior to AESARA, Sameera worked within the industry at Biogen International GmbH in Zug, Switzerland and Novartis AG in Basel, Switzerland and Novartis Private Limited in Hyderabad, India.

Claudia Roeder, PhD

With more than 25 years of industry experience, Claudia has specialized over the past 15 years on advising leading pharmaceutical companies’ global and local HEOR and market access/pricing teams. With a strong focus on transparency and user-friendliness, Claudia has led projects for the creation of product specific value stories, high-quality value dossiers as well as interactive value communication materials.

She has also managed various health economic evaluations and led multi-regional trainings of internal and external stakeholders covering therapeutic areas such as diabetes, CNS, neurology, cardiovascular disease, fertility, and oncology. Successful leadership for Claudia means active listening, empowered teamwork and collaborative, outcome focused problem solving.

Kate Burslem, MSc

has over 20 years’ experience in the healthcare field in Europe and the US. She joins AESARA from AbbVie, where she most recently led the global HEOR team supporting AbbVie’s Toxin Therapeutic & Eyecare portfolios, having previously held leadership positions in the Neuroscience & Gastrointestinal therapeutic areas. Before joining AbbVie, Kate held positions of increasing responsibility in HEOR at Boehringer Ingelheim, within both the US and UK affiliates. Prior to joining the pharmaceutical industry, Kate worked as a Technical Analyst at the UK’s National Institute for Health & Care Excellence.  She began her career in employee benefits consulting, where her work on international medical insurance plan design inspired her to go back to school and study health economics.

Kate has a strategic mindset, coupled with strong analytical skills in the key HEOR disciplines of real-world evidence, economic modeling and patient-reported outcomes. She enjoys developing value and access strategies at all stages of the product lifecycle and fostering alignment across multi-disciplinary teams to achieve a common goal. Her career has spanned a broad range of therapeutic areas including immunology, oncology, neuroscience, respiratory, cardiovascular and diabetes.

Case studies

European Sequencing Strategy

A US-headquartered specialty biotech acquired an innovative oncology asset with multiple indications of interest…

European HTA Submission Programme

Planning and execution of health technology assessment (HTA), price, reimbursement submissions in European markets…

European Asset Due Diligence

Bringing European markets’ price, access and reimbursement insight to support global in-licensing decisions…


Contact us

Fill out the form below, and we will be in touch shortly.